JP2023542312A5 - - Google Patents

Info

Publication number
JP2023542312A5
JP2023542312A5 JP2023516810A JP2023516810A JP2023542312A5 JP 2023542312 A5 JP2023542312 A5 JP 2023542312A5 JP 2023516810 A JP2023516810 A JP 2023516810A JP 2023516810 A JP2023516810 A JP 2023516810A JP 2023542312 A5 JP2023542312 A5 JP 2023542312A5
Authority
JP
Japan
Prior art keywords
transmembrane
domain
nucleic acid
fusion protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023516810A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542312A (ja
JP7685044B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/117886 external-priority patent/WO2022053036A1/en
Publication of JP2023542312A publication Critical patent/JP2023542312A/ja
Publication of JP2023542312A5 publication Critical patent/JP2023542312A5/ja
Application granted granted Critical
Publication of JP7685044B2 publication Critical patent/JP7685044B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023516810A 2020-09-13 2021-09-13 受容体tac技術による膜結合タンパク質の下方制御 Active JP7685044B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063077658P 2020-09-13 2020-09-13
US63/077,658 2020-09-13
US202163144945P 2021-02-02 2021-02-02
US63/144,945 2021-02-02
US202163173476P 2021-04-11 2021-04-11
US63/173,476 2021-04-11
PCT/CN2021/117886 WO2022053036A1 (en) 2020-09-13 2021-09-13 Downregulation of membrane-bound proteins by receptor tac technology

Publications (3)

Publication Number Publication Date
JP2023542312A JP2023542312A (ja) 2023-10-06
JP2023542312A5 true JP2023542312A5 (cg-RX-API-DMAC7.html) 2024-06-26
JP7685044B2 JP7685044B2 (ja) 2025-05-28

Family

ID=80629753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516810A Active JP7685044B2 (ja) 2020-09-13 2021-09-13 受容体tac技術による膜結合タンパク質の下方制御

Country Status (5)

Country Link
US (1) US20230355764A1 (cg-RX-API-DMAC7.html)
EP (1) EP4178986B1 (cg-RX-API-DMAC7.html)
JP (1) JP7685044B2 (cg-RX-API-DMAC7.html)
CN (1) CN116368152A (cg-RX-API-DMAC7.html)
WO (1) WO2022053036A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4565333A4 (en) * 2022-08-04 2026-07-22 Univ Michigan GRAIL-1 PEPTIDE-BASED PRODUCTS AND METHODS
CN116063579B (zh) * 2022-11-17 2026-02-27 安徽医科大学 一种靶向人cd47的嵌合抗原受体、表达嵌合抗原受体的巨噬细胞及其应用
WO2024168276A2 (en) * 2023-02-09 2024-08-15 Cargo Therapeutics, Inc. Compositions and methods for immunotherapies
WO2025011459A1 (en) * 2023-07-07 2025-01-16 Nanjing Legend Biotech Co., Ltd. Proteins and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2931898E (pt) * 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
CA2994969A1 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
CA2937157A1 (en) * 2016-07-25 2018-01-25 Ucl Business Ltd Protein-based t-cell receptor knockdown
US20200087681A1 (en) * 2016-12-21 2020-03-19 Ucl Business Plc Therapeutic cells
CN110753693A (zh) * 2016-12-23 2020-02-04 阿尔维纳斯运营股份有限公司 Egfr蛋白水解靶向嵌合分子和相关使用方法
GB201710620D0 (en) 2017-07-03 2017-08-16 Glaxosmithkline Intellectual Property Ltd Targeted protein degradation
CA3071282A1 (en) * 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
WO2019089592A1 (en) * 2017-10-31 2019-05-09 The General Hospital Corporation Molecular switch-mediated control of engineered cells
JP2021515582A (ja) * 2018-03-16 2021-06-24 コーネル・ユニバーシティーCornell University 操作された細菌ユビキチンリガーゼ模倣物を用いる、幅広い範囲にわたるプロテオーム編集
WO2020146250A1 (en) * 2019-01-07 2020-07-16 Dana-Farber Cancer Institute, Inc. SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS
US20220133792A1 (en) * 2019-02-01 2022-05-05 The Trustees Of Dartmouth College Signaling platforms for chimeric antigen receptor t cells
CN113088495B (zh) * 2020-01-09 2024-08-16 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用

Similar Documents

Publication Publication Date Title
Hutchings et al. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
JP7822587B2 (ja) ヘテロ二量体化Igドメイン
JP2025138715A5 (cg-RX-API-DMAC7.html)
JP2024023228A5 (cg-RX-API-DMAC7.html)
Lebbink et al. The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction
JP6025502B2 (ja) B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物
JP6101638B2 (ja) 多価ヘテロマルチマー足場設計及び構築物
JP2020517294A5 (cg-RX-API-DMAC7.html)
JP2025142045A5 (cg-RX-API-DMAC7.html)
JP2023518134A5 (cg-RX-API-DMAC7.html)
JP2022505663A5 (cg-RX-API-DMAC7.html)
US20200157178A1 (en) Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer
CA2956126A1 (en) Sirp-alpha immunoglobulin fusion proteins
JP2020511949A5 (cg-RX-API-DMAC7.html)
JP2023549116A (ja) 選択性が増大した多標的二重特異性抗原結合分子
Rao et al. Mechanism of homophilic binding mediated by the neural cell adhesion molecule NCAM. Evidence for isologous interaction.
CA2430528A1 (en) Hybrid antibodies
JP2012514997A (ja) 組換え一価抗体
JP2024504728A5 (cg-RX-API-DMAC7.html)
JPWO2015146438A1 (ja) ヒト上皮増殖因子受容体を標的とした二重特異性抗体
EP3590578A1 (en) Muscarinic acetylcholine receptor binding agents and uses thereof
US20030138440A1 (en) Multimeric proteins and methods of making and using same
JP2024515919A5 (cg-RX-API-DMAC7.html)
CN119137147A (zh) 具有增加的选择性的多链多靶向性双特异性抗原结合分子
JP2023527908A (ja) 4-1bbをターゲティングする多量体免疫調節物質